Envveno Medical Corp (NVNO)

$10.29 -0.10 (-0.96%)
Market Cap 7.03M
Revenue (ttm) 0.00
Net Income (ttm) -19.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,100
Avg Vol 17,916
Day's Range N/A - N/A
Shares Out 683,000.00
Stochastic %K 7%
Beta 1.10
Analysts Sell
Price Target $30.00

Company Profile

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 261 2900
Address:
70 Doppler, Irvine, United States
Biotech_Pharma_Investor
Biotech_Pharma_Investor Aug. 21 at 2:27 PM
$NVNO seems like a good candidate for a PIPE (although I would much prefer company waits for initial safety readout before raising cash)
0 · Reply
Yingtrader7
Yingtrader7 Aug. 20 at 3:44 PM
$NVNO BYE BYE ADIOS AMIGO
0 · Reply
Yingtrader7
Yingtrader7 Aug. 18 at 6:40 PM
$NVNO so quiet here
0 · Reply
Yingtrader7
Yingtrader7 Aug. 18 at 4:58 PM
$NVNO nobody around
0 · Reply
Yingtrader7
Yingtrader7 Aug. 17 at 11:37 PM
$NSYS Jimmy Rockin The Dock, $NVNO
0 · Reply
MoneyMacG
MoneyMacG Aug. 17 at 9:23 PM
$NSYS $NCI $AFJK $NVNO r
0 · Reply
MoneyMacG
MoneyMacG Aug. 17 at 7:35 PM
$NCI $FXHO $AFJK $NVNO $NIPG gem$$$
0 · Reply
Yingtrader7
Yingtrader7 Aug. 17 at 7:13 PM
$NSYS did you catch that $NVNO bounce
0 · Reply
Yingtrader7
Yingtrader7 Aug. 17 at 6:42 PM
$NVNO awesome for now will it hold
0 · Reply
STACKD0E
STACKD0E Aug. 17 at 6:27 PM
$NVNO 🙃✨️
0 · Reply
Latest News on NVNO
enVVeno Medical files $100M mixed securities shelf

2026-08-21T20:35:25.000Z - 2 days ago

enVVeno Medical files $100M mixed securities shelf

enVVeno announces publication of independent health economic study

2026-08-04T12:50:38.000Z - 19 days ago

enVVeno announces publication of independent health economic study

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

Aug 4, 2026, 8:46 AM EDT - 19 days ago

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

enVVeno Medical reports Q2 EPS ($5.37) vs. ($11.52) last year

2026-07-31T12:41:31.000Z - 23 days ago

enVVeno Medical reports Q2 EPS ($5.37) vs. ($11.52) last year

enVVeno Medical sees cash runway into 3Q27

2026-07-31T12:41:17.000Z - 23 days ago

enVVeno Medical sees cash runway into 3Q27

enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2H26

2026-07-31T12:40:54.000Z - 23 days ago

enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2H26

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

Jul 31, 2026, 8:30 AM EDT - 23 days ago

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

enVVeno Medical highlights newly issued U.S. patent

2026-07-15T12:55:49.000Z - 5 weeks ago

enVVeno Medical highlights newly issued U.S. patent

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

enVVeno Medical secures U.S. patent for enVVe system

2026-07-07T12:45:24.000Z - 6 weeks ago

enVVeno Medical secures U.S. patent for enVVe system

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

Jul 7, 2026, 8:29 AM EDT - 6 weeks ago

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

enVVeno Medical upgraded to Buy from Neutral at Ladenburg

2026-07-06T15:05:07.000Z - 6 weeks ago

enVVeno Medical upgraded to Buy from Neutral at Ladenburg

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

Jun 22, 2026, 9:00 AM EDT - 2 months ago

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Jun 2, 2026, 9:01 AM EDT - 2 months ago

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

May 12, 2026, 9:02 AM EDT - 3 months ago

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year

2026-05-07T20:35:58.000Z - 3 months ago

enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year

enVVeno Medical sees cash runway into 3Q27

2026-05-07T20:34:39.000Z - 3 months ago

enVVeno Medical sees cash runway into 3Q27

enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter

2026-05-07T20:33:52.000Z - 3 months ago

enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

May 7, 2026, 8:05 AM EDT - 3 months ago

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study

2026-04-29T14:53:15.000Z - 4 months ago

enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

Apr 29, 2026, 8:05 AM EDT - 4 months ago

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

enVVeno Medical reports FY25 EPS ($33.06) vs. ($44.53) last year

2026-03-27T12:40:21.000Z - 5 months ago

enVVeno Medical reports FY25 EPS ($33.06) vs. ($44.53) last year

enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2026

2026-03-27T12:39:51.000Z - 5 months ago

enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2026

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

Mar 27, 2026, 8:30 AM EDT - 5 months ago

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

Mar 3, 2026, 2:40 PM EST - 6 months ago

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

enVVeno Medical regains compliance with Nasdaq minimum bid price rule

2026-02-04T13:46:53.000Z - 7 months ago

enVVeno Medical regains compliance with Nasdaq minimum bid price rule

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 4, 2026, 8:30 AM EST - 7 months ago

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

enVVeno Medical trading halted, news pending

2026-01-17T00:50:35.000Z - 7 months ago

enVVeno Medical trading halted, news pending

enVVeno Medical board approves 1-for-35 reverse stock split

2026-01-15T13:20:22.000Z - 7 months ago

enVVeno Medical board approves 1-for-35 reverse stock split

enVVeno Medical Announces Reverse Stock Split

Jan 15, 2026, 8:00 AM EST - 7 months ago

enVVeno Medical Announces Reverse Stock Split

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

Nov 26, 2025, 8:48 AM EST - 9 months ago

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

enVVeno Medical trading resumes

2025-11-13T22:30:26.000Z - 10 months ago

enVVeno Medical trading resumes

enVVeno Medical receives unfavorable FDA decision for VenoValve

2025-11-13T22:05:19.000Z - 10 months ago

enVVeno Medical receives unfavorable FDA decision for VenoValve

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Nov 13, 2025, 5:00 PM EST - 10 months ago

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 8:05 AM EDT - 10 months ago

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Sep 26, 2025, 8:45 AM EDT - 11 months ago

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

enVVeno Medical Updates Regulatory Status of VenoValve(R)

Sep 15, 2025, 8:45 AM EDT - 1 year ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 20, 2025, 7:00 AM EDT - 1 year ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 15, 2025, 9:21 AM EDT - 1 year ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Aug 4, 2025, 9:05 AM EDT - 1 year ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 1, 2025, 8:00 AM EDT - 1 year ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 1 year ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Jun 6, 2025, 8:05 AM EDT - 1 year ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 19, 2025, 8:05 AM EDT - 1 year ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 13, 2025, 8:45 AM EDT - 1 year ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

May 1, 2025, 8:05 AM EDT - 1 year ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 23, 2025, 8:00 AM EDT - 1 year ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Apr 16, 2025, 8:30 AM EDT - 1 year ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Mar 31, 2025, 9:00 AM EDT - 1 year ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 28, 2025, 8:00 AM EST - 1 year ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 19, 2025, 8:45 AM EST - 1 year ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Feb 7, 2025, 9:00 AM EST - 1 year ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Dec 16, 2024, 8:50 AM EST - 1 year ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 27, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 20, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Nov 19, 2024, 8:15 AM EST - 1 year ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 24, 2021, 9:00 AM EDT - 5 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 21, 2021, 4:00 PM EDT - 5 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 15, 2021, 8:05 AM EDT - 5 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Sep 7, 2021, 8:05 AM EDT - 5 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 19, 2021, 8:00 AM EDT - 5 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Aug 3, 2021, 8:05 AM EDT - 5 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Jul 8, 2021, 9:05 AM EDT - 5 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 23, 2021, 12:40 PM EDT - 5 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Apr 5, 2021, 7:30 AM EDT - 5 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Biotech_Pharma_Investor
Biotech_Pharma_Investor Aug. 21 at 2:27 PM
$NVNO seems like a good candidate for a PIPE (although I would much prefer company waits for initial safety readout before raising cash)
0 · Reply
Yingtrader7
Yingtrader7 Aug. 20 at 3:44 PM
$NVNO BYE BYE ADIOS AMIGO
0 · Reply
Yingtrader7
Yingtrader7 Aug. 18 at 6:40 PM
$NVNO so quiet here
0 · Reply
Yingtrader7
Yingtrader7 Aug. 18 at 4:58 PM
$NVNO nobody around
0 · Reply
Yingtrader7
Yingtrader7 Aug. 17 at 11:37 PM
$NSYS Jimmy Rockin The Dock, $NVNO
0 · Reply
MoneyMacG
MoneyMacG Aug. 17 at 9:23 PM
$NSYS $NCI $AFJK $NVNO r
0 · Reply
MoneyMacG
MoneyMacG Aug. 17 at 7:35 PM
$NCI $FXHO $AFJK $NVNO $NIPG gem$$$
0 · Reply
Yingtrader7
Yingtrader7 Aug. 17 at 7:13 PM
$NSYS did you catch that $NVNO bounce
0 · Reply
Yingtrader7
Yingtrader7 Aug. 17 at 6:42 PM
$NVNO awesome for now will it hold
0 · Reply
STACKD0E
STACKD0E Aug. 17 at 6:27 PM
$NVNO 🙃✨️
0 · Reply
Yingtrader7
Yingtrader7 Aug. 17 at 3:56 PM
$NVNO wow you see $IPST
0 · Reply
Yingtrader7
Yingtrader7 Aug. 17 at 3:47 PM
$NVNO thin trades
0 · Reply
Yingtrader7
Yingtrader7 Aug. 15 at 7:38 PM
$NSYS WOW I LIKE $NVNO why it so stable
1 · Reply
_ProfessorGamma
_ProfessorGamma Aug. 10 at 2:39 PM
$NVNO I haven't lost interest
1 · Reply
haupman
haupman Aug. 6 at 4:22 PM
$NVNO when's the $10 offering?
1 · Reply
envvenomedical
envvenomedical Aug. 4 at 1:36 PM
$NVNO Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical’s Replacement Venous Valve Therapy Compared to Standard of Care Treatments https://envveno.com/independent-health-economic-study-recently-published-in-journal-of-vascular-surgery-reports-economic-dominance-of-envveno-medicals-replacement-venous-valve-therapy-compared-to-standard-of-care-treat/
1 · Reply
STACKD0E
STACKD0E Aug. 4 at 12:53 PM
$NVNO 👀
0 · Reply
envvenomedical
envvenomedical Jul. 31 at 1:09 PM
$NVNO Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve https://envveno.com/envveno-medical-reports-second-quarter-2026-financial-results-and-advances-towards-fda-pivotal-trial-for-first-in-class-non-surgical-replacement-venous-valve/
0 · Reply
Icemanja
Icemanja Jul. 21 at 7:58 PM
$NVNO Volume finally showed up. When they will need that ATM soon !!!
0 · Reply
Icemanja
Icemanja Jul. 15 at 4:34 PM
$NVNO Betting Agianst Rob Berman was the only way to make money in anything he does no different this time around. The few investors that did take a chance on this company got burnt multiple times. No matter what PR they put out interest will be low. At this price and MC someone could control the whole float for 7 mil. Management reputation is whats dragging this company down.
0 · Reply